Combination therapy with alisertib enhances the anti-tumor immunity induced by a liver cancer vaccine

iScience, Год журнала: 2025, Номер 28(4), С. 112120 - 112120

Опубликована: Март 15, 2025

Alisertib is a potent aurora A kinase inhibitor in clinical trials for cancer treatment, but its efficacy on vaccines remains unclear. Here, we developed DNA vaccine targeting glypican-3 (pGPC3) and evaluated with alisertib hepatocellular carcinoma (HCC) models. The combination therapy of pGPC3 significantly inhibited subcutaneous tumor growth, enhanced the induction maturation CD11c+ CD8+CD11c+ dendritic cells (DCs), expanded tumor-specific CD8+ T cell responses. depletion abolished anti-tumor effects, underscoring essential role functional Moreover, combined treatment promoted memory induction, providing long-term protection. In liver orthotopic models, demonstrated therapeutic through These results indicate that enhances vaccine's effect, offering promising strategy HCC treatment.

Язык: Английский

---

Iparomlimab and Tuvonralimab: First Approval

Drugs, Год журнала: 2025, Номер unknown

Опубликована: Апрель 1, 2025

Язык: Английский

---

Comparative efficacy of tislelizumab plus lenvatinib and tislelizumab alone against advanced hepatocellular carcinoma after lenvatinib failure: a real-world study

BMC Cancer, Год журнала: 2025, Номер 25(1)

Опубликована: Апрель 16, 2025

This study evaluated the effectiveness and safety of tislelizumab plus lenvatinib (TL group) monotherapy (T in patients with stage C hepatocellular carcinoma (HCC) according to Barcelona Clinic Liver Cancer (BCLC) staging system after failure, it analyzed factors influencing TL as a second-line treatment. retrospective analysis involved 51 treated at single center between January 2019 July 2023. Survival outcomes tumor responses were compared T groups. Prognostic for overall survival (OS) progression-free (PFS) identified using Cox proportional hazard regression models. Among BCLC advanced HCC who experienced treatment median PFS was significantly longer group than (6.8 months vs. 4.5 months, p = 0.003), OS notably extended (14.0 10.4 0.012). Although disease control rate (64% 53.8%, 0.461) objective response (20% 7.7%, 0.202) numerically higher group, these differences did not reach significance. Child-Pugh B liver function independent prognostic poor OS, whereas only an factor PFS, PFS. Subgroup demonstrated benefit A 12.0 0.013) but those (7.7 6.1 0.225). In most frequent treatment-related adverse events (AEs) hand-foot skin reaction (32%), hypertension (28%), diarrhea hypothyroidism (20%). Grade 3 or AEs occurred 24% grade AEs. The incidence comparable two As treatment, combination well tolerated associated improved versus alone HCC, particularly function.

Язык: Английский

---

Prognostic impact of body composition in hepatocellular carcinoma patients undergoing interventional and systemic therapy

Frontiers in Nutrition, Год журнала: 2025, Номер 12

Опубликована: Апрель 16, 2025

Background Primary liver cancer, predominantly hepatocellular carcinoma (HCC), is a leading cause of cancer-related deaths globally. Despite advances in targeted therapy and immunotherapy, survival rates for advanced HCC remain low. Combining hepatic artery infusion chemotherapy (HAIC) with systemic therapies shows potential, but identifying patients who benefit most challenging. Body composition, including sarcopenia myosteatosis, has been linked to cancer prognosis, its role receiving HAIC immunotherapies unclear. Methods This retrospective study analyzed 158 treated HAIC, tyrosine kinase inhibitors, anti-PD-1 immunotherapy from January 2021 October 2024. composition was assessed via CT scans at the L3 level, defined by skeletal muscle index (SMI) myosteatosis density (SMD). Progression-free (PFS) overall (OS) were evaluated, Cox regression analyses identified prognostic factors. Results Sarcopenia cutoffs 47.1 cm 2 /m (males) 38.2 (females); 40.8 HU 38.9 (females). Sarcopenic had lower BMI ( p < 0.001) higher ALBI scores = 0.006). Tumor response (ORR 53.4%, DCR 77.9%) similar between sarcopenic non-sarcopenic groups 0.531 0.699). Myosteatosis showed no significant differences ORR (54.0%) or (77.0%) 0.693 0.872). Median PFS did not differ (9.53 months) (13.87 0.536). However, significantly shorter OS (20.80 vs. 35.97 months, 0.005). also correlated 0.021). Multivariate analysis as an independent risk factor (HR: 0.527, 0.017), alongside AFP levels tumor number. Conclusion predict poor prognosis immunotherapy. OS, highlighting importance body prognosis. No associations found PFS.

Язык: Английский

---

Exosome-based immunotherapy in hepatocellular carcinoma

Clinical and Experimental Medicine, Год журнала: 2025, Номер 25(1)

Опубликована: Апрель 24, 2025

Язык: Английский

---